Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Context Therapeutics Inc.NASDAQ: CNTX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) dips below year-ago levels

Q1 FY2026 weighted avg shares (diluted) of 95.18M shares fell 0.0% year over year, behind the +30.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +81.3% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.0% toward the trailing-twelve-month pace of +30.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
95.18M+3.6% QoQ
Last fiscal yearDec 2025
95.19M+62.9% YoY
LTMMar 2026
94.36M+30.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.0%——
1 year+62.9%——
3-year CAGR+81.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
95.19M USD
Year-over-year change
+62.9%
4-year CAGR
+140.7%

Weighted Avg Shares (Diluted) vs competitors

How CNTX compares with its peers on the latest reported figures

  • CNTX's LTM Mar 2026 weighted avg shares (diluted) of 94.36M shares is the highest of the 11 companies compared; the peer median is 59.46M shares.
  • Its year-over-year change of +30.6% is the 5th highest of 11, against a peer median of +9.7%.
  • Over three fiscal years its annual growth of +81.3% compares with a peer median of +8.9%.
CNTX Competitors Peer median
Weighted Avg Shares (Diluted) for CNTX and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
WHWKWhitehawk Therapeutics IncLTM Mar 202669.18M +155.7%+40.1%
IFRXInflaRx N.V.LTM Mar 202668.86M +14.8%+15.0%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 202642.44M +3.8%+2.8%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
IMAImageneBio IncLTM Mar 202619.79M -59.0%-48.8%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
Peer median (excluding CNTX) 59.46M+9.7%+8.9%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.81M7.09M17.78M22.7M31.86M
Selling, General & Admin3.63M7.79M7.29M7.22M7.85M
Operating Expenses10.53M15.38M25.07M29.92M39.7M
Depreciation & Amortization09.27K12.04K10.88K16.25K
EBITDA(7.44M)(14.87M)(23.95M)(26.71M)(36.11M)
EBITDA Margin—————
Operating Income(10.53M)(15.38M)(25.07M)(29.92M)(39.7M)
Operating Margin—————
Interest Income64547.27K1.16M3.2M3.38M
Interest Expense64.24K547.27K000
Other Income / Expenses68.95K545.26K1.11M3.2M3.58M
Income Before Tax(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Net Margin—————
EPS (Basic)(3.69)(0.93)(1.50)(0.46)(0.38)
EPS (Diluted)(3.69)(0.93)(1.50)(0.46)(0.38)
Weighted Avg Shares2.83M15.97M15.97M58.42M95.19M
Weighted Avg Shares (Diluted)2.83M15.97M15.97M58.42M95.19M

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.